Navigation Links
Ground Zero Pharmaceuticals Announces Expansion of Global Consulting in Somatic Cell Therapies
Date:10/5/2010

IRVINE, Calif., Oct. 5 /PRNewswire/ -- GZP is pleased to announce that it has expanded its capabilities for strategic regulatory and product development support of gene therapy and somatic cell therapies, including treatment vaccines for cancer and other serious or life-threatening diseases.  New senior associates with expertise in manufacturing and clinical development in these expanding areas allow GZP to provide its clients with hands-on guidance through the FDA regulatory review process.  Firms in the US and Australia have already taken advantage of this expertise and are preparing to launch programs in Phase 1, 2 and 3 clinical trials for their "new concept" products.  Two of our staff, Dr. Chaline Brown and Ms. Tisha Templeton, will be attending and presenting this month at the TRX10 and AusBiotech conferences in Brisbane and Melbourne Australia, respectively, and will be available to discuss these added capabilities.  They will be available for partnering meetings as well.

Specifics of these Australian speaking engagements are:

12 October 2010 – Brisbane – TRX10 – "Regulations Pertinent to Pharmacogenomics and Biomarkers in Europe and USA"

20 October 2010 – Melbourne – AusBiotech 2010 - "Dealing with the FDA – What's Hot?"

GZP continues to believe that early, frequent, and creative communication with the FDA (including informal targeted review of specific issues that can slow down development programs at both early and mid-stages) can lead to more successful medical product development, attracting more funding in today's difficult financial climate.

In 2010, GZP increased its global client base at all phases of development across therapeutic areas such as oncology and neurological disease, and created and submitted several INDs.

Pre-pre-IND, pre-IND and mid-phase meetings with the FDA led to acceleration of drug and biologic development programs for our clients.  Our medical device practice also expanded and included consultation with California's Food and Drug Branch as well as the FDA.

According to Evan Siegel, "We are pleased to see that the need for continued review and approval of key medical products and the determination of our clients to be successful has contributed to the recovery from the global financial crisis across industry.  Our client's dedication, loyalty, their referrals, and the excellence of our staff and associates in maintaining an integrated, cohesive and client-specific approach furthers the commitment of GZP to provide the highest quality ethical and knowledgeable consulting."

Based in Irvine, a major biotechnology center in Southern California, Ground Zero Pharmaceuticals, Inc. is a regulatory affairs and product development consulting firm providing strategic and tactical services to the pharmaceutical, biotechnology and medical device industries.  These include regulatory representation and submissions (paper and electronic), strategic medical consulting, preclinical/nonclinical planning, auditing and review of clinical, nonclinical and CMO sites, medical writing, chemistry, manufacturing and controls consulting, clinical assessment, data management, biostatistics, and project management.  GZP has resources throughout the US, Canada, Australia and Europe, and a wholly owned subsidiary in Brisbane and Melbourne, Australia.

Web Site: http://www.groundzerous.com

For further information please contact Ms. Tisha Templeton, Senior Vice President of Finance and Operations, Ground Zero Pharmaceuticals, Inc., +1-949-852-3666, fax, +1-949-852-3655, ttempleton@groundzerous.com.


'/>"/>
SOURCE Ground Zero Pharmaceuticals
Copyright©2010 PR Newswire.
All rights reserved

Related biology technology :

1. Medicago holds official groundbreaking ceremony for its U.S. commercial grade vaccine facility
2. SPI Pharma Gains Ground in Roquette Patent Dispute
3. BellBrook Labs Launches Groundbreaking New Microplate for High Content Chemotaxis Assays in a Stable Gradient
4. BioMed Realty Trust Breaks Ground on 176,000 Square Foot R&D Facility for Isis Pharmaceuticals in Carlsbad, California
5. Groundbreaking International Training Lab to Strengthen Food Safety in U.S. and Globally
6. Under new leadership, Kavli Institute at Cornell evolves from a think tank to a proving ground
7. Texas-Based Consortium Announces Project GreenVax: A Groundbreaking Vaccine Manufacturing Research Program
8. Butler Hospital Neurologist Lead Author of Ground Breaking Bio-Engineered Treatment Study for Alzheimers Disease
9. Promise of a New Lupus Treatment Is a Groundbreaking Achievement
10. Novavax and CPL Biologicals Break Ground on New Influenza Vaccine Manufacturing Facility in India
11. Grifols Breaks Ground on New National Testing Laboratory
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/9/2016)... (PRWEB) , ... February 09, 2016 , ... ... its latest innovations on its free and validated Electronic Data Capture (EDC) system ... the Outsourcing in Clinical Trials West Coast 2016 Conference in San Mateo, California ...
(Date:2/9/2016)... 9, 2016  DNAtrix, a clinical stage, ... announced that its lead product, DNX-2401, has ... an orphan medicinal product for the treatment ... glioma, strikes approximately 25,000 people a year ... http://photos.prnewswire.com/prnh/20160208/330986LOGO --> http://photos.prnewswire.com/prnh/20160208/330986LOGO ...
(Date:2/9/2016)... Feb. 9, 2016 ... 2016", report provides in depth insights on ... around the Protein-Tyrosine Phosphatase 1B (PTP1B) Inhibitors. ... in various stages of development including Discovery, ... III and Preregistration. Report covers the product ...
(Date:2/8/2016)... 8, 2016 Novan, Inc. today announced that Director ... of Directors of Novan. In addition, Robert Keegan has ... North Carolina . --> North Carolina ... it received a total of $32.8 million of net proceeds in ... investor network originating throughout the Research Triangle area of ...
Breaking Biology Technology:
(Date:2/2/2016)... , Feb. 2, 2016 This BCC ... bioinformatic market by reviewing the recent advances in ... that drive the field forward. Includes forecast through ... Identify the challenges and opportunities that exist in ... software solution developers, as well as IT and ...
(Date:2/2/2016)... 2016 Technology Enhancements Accelerate Growth of X-ray Imaging ... digital and computed radiography markets in Thailand ... Indonesia (TIM). It provides an in-depth ... well as regional market drivers and restraints. The study ... and market attractiveness, both for digital and computed radiography. ...
(Date:2/2/2016)... Feb. 2, 2016  Based on its recent ... Sullivan recognizes US-based Intelligent Retinal Imaging Systems (IRIS) ... Award for New Product Innovation. IRIS, a prominent ... North America , is poised to set ... diabetic retinopathy market. The IRIS technology presents superior ...
Breaking Biology News(10 mins):